Aromatase inhibitors (AIs) are becoming the hormonal ... or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole ...

The results of ongoing trials will assist clinicians in deciding among the various options for adjuvant hormonal therapy in postmenopausal women with EBC. In particular, there will be progress ...

Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as tamoxifen and aromatase inhibitors. But around one in five of these cases recur within 10 years, and nearly ...

There are three aromatase inhibitors available: Faslodex belongs to a group of medicines known as hormonal or endocrine therapy. It works as an estrogen receptor blocker. Faslodex is given as an ...